Nontuberculous mycobacteria (NTM) are a group of biologically diverse, ubiquitous and naturally multi-drug resistant bacteria with facultative pathogenicity. Recent data suggest that their clinical significance is increasing worldwide and that susceptible individuals may be at risk for infection via contaminated surfaces and aerosols. These individuals often have a predisposition for chronic respiratory diseases, e. g. bronchiectasis, chronic obstructive pulmonary disease (COPD) and cystic fibrosis and these conditions frequently share the same unspecific signs and symptoms with NTM pulmonary disease (NTM-PD). As a consequence, the diagnosis of NTM-PD, which is established based on clinical, radiological and microbiological criteria, is often delayed. Treating NTM-PD is more demanding than treating pulmonary tuberculosis as therapy is generally more tedious, toxic and expensive as well as being prone to failure. Patient and pathogen-specific factors guide the choice of an appropriate antimicrobial combination regimen, which should comply with national and international recommendations. Adverse events are common, should be anticipated and closely monitored. If infections with infrequently encountered mycobacterial species and severe or refractory disease occur, an interdisciplinary approach should be used, involving infectious disease specialists, experienced thoracic surgeons and referral to an NTM specialist center.
- Ringshausen, F. C.; Rademacher, J.
Keywords
- Anti-Bacterial Agents/*administration & dosage
- Diagnosis, Differential
- Evidence-Based Medicine
- Humans
- Lung Diseases/*diagnosis/*drug therapy/microbiology
- Mycobacterium Infections, Nontuberculous/*diagnosis/*drug therapy/microbiology
- Treatment Outcome
- Azithromycin
- Bronchiectasis
- Cystic fibrosis
- Ethambutol
- Pulmonary disease, chronic obstructive